Neurocrine Biosciences Financials - Benzinga

Neurocrine Biosciences Inc

NBIXNASDAQ

Trade with Public

Trade with Public

$140.44

2.041.47%

近くで: Sep 28, 5:00 PM EST

$140.80

0.360.26%

時間外: 7:27 PM EST

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Neurocrine Biosciences Financials

Neurocrine Biosciences (NBIX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Neurocrine Biosciences Q2 Adj. EPS $2.85 Beats $1.34 Estimate, Sales $959.000M Beat $883.259M Estimate

Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings of $2.85 per share which beat the analyst consensus estimate of $1.34 by 112.69 percent. This is a 72.73 percent increase over earnings of $1.65 per share

Benzinga Newsdesk

PRO
Neurocrine Biosciences Q1 Adj. EPS $1.94 Beats $1.61 Estimate, Sales $814.500M Beat $763.112M Estimate

Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings of $1.94 per share which beat the analyst consensus estimate of $1.61 by 20.5 percent. This is a 177.14 percent increase over earnings of $0.70 per share

Benzinga Newsdesk

Earnings Scheduled For May 5, 2026

Benzinga Insights

Analysts Stay Bullish As Neurocrine Shares Tumble On Disappointing Ingrezza Guidance

Neurocrine shares fell 8% after mixed earnings, strong Ingrezza sales, and a 2026 outlook that met expectations. Analysts see long-term upside despite short-term pressure.

Vandana Singh

Neurocrine Biosciences Q4 Earnings Assessment

Benzinga Insights

PRO
Neurocrine Biosciences Expects FY26 INGREZZA Net Product Sales Of $2.70B-$2.80B

Full-Year 2026 Financial Guidance Range(in millions)Low HighINGREZZA Net Product Sales 1$ 2,700 $

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved